New Delhi, April 22 -- Eli Lilly's acquisition of Kelonia Therapeutics has quickly emerged as one of the most significant biotech deals of 2026, highlighting the pharmaceutical giant's aggressive push into next-generation cancer therapies. The deal, valued at $3.25 billion upfront and potentially reaching $7 billion through milestone-based payments, underscores Lilly's strategy to strengthen its oncology pipeline and compete in the rapidly evolving global cancer drug market, estimated at around $240 billion. The move also reflects a broader industry shift toward innovative cell and gene therapies, particularly in blood cancers such as multiple myeloma.

At the center of the acquisition is Kelonia's pioneering "in vivo CAR-T" technology, w...